ADAMTS13 and thrombotic thrombocytopenic purpura: Median time to recovery of ADAMTS13 activity was longer in patients who received rituximab versus patients who did not receive rituximab (≥ 10%: 24.8 vs 6.3 days; ≥ 20%: 31.8 vs 6.4 days; ≥ 60%: 49.8 vs 23.9 days) and in patients experiencing an initial TTP episode versus patients experiencing a subsequent TTP episode (≥ 10%: 18.5 vs 6.9 days; ≥ 20%: 28.8 vs 13.7 days; ≥ 60%: 47.5 vs 18.6 days).